1. Rutman RJ, Cantarow A, Paschkis KE. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res 1954;14:119-123.
2. Heidelberger C, Chaudhuri NK, Danneberg PB, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957;179:663-666.
3. Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Gann 1979;70:209-214.
4. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer: implications for screening. Chest 1992;101:1013-1018.
5. Vrdoljak E, Mise K, Sapunar D, et al. Survival analysis of untreated patients with non-small-cell lung cancer. Chest 1994;106:1797-1800.
7. Sohn KH, Kwak YT, Cho KH, Kim JH, Lee DY, Lee HK, et al. A Survival Study of Surgically Treated Lung Cancer in Korea. J Korean Med Sci 1991;6(2):135-145.
8. Martini N, Melamed MR. Occult carcinoma of the lung. Ann Thorac Surg 1980;30:215-223.
9. Padilla J, Calvo V, Penalver JC, et al. Surgical results and prognostic factors in early non-small-cell lung cancer. Ann Thorac Surg 1997;63:2324-2326.
10. Ichinose Y, Hara N, Ohta M, et al. Is T factor of the TNM staging system a predominant prognostic factor in pathologic stage I non-small-cell lung cancer? A multivariate prognostic factor analysis of 151 patients J Thorac Cardiovasc Surg 1993;106:90-94.
11. Ichinose Y, Yano T, Asoh H, et al. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer: an analysis in each pathologic stage. J Thorac Cardiovasc Surg 1994;107:1087-1094.
12. Macchiarini P, Fontanini G, Hardin JM, et al. Most peripheral, node-negative non-small-cell lung cancers have low proliferative rates and no intratumoral and pertumoral blood and lymphatic vessel invasion: rationale for treatment with wedge resection alone. J Thorac Cardiovasc Surg 1992;104:892-899.
13. Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106:80-89.
15. Churchill ED, Sweet RH, Scannell JG, et al. Futher studies in the surgical management of carcinoma of the lung. J Thorac Surg 1958;36:301-308.
16. Feld R, Rubinstein LV, Weisenberger TH, et al. Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984;2:1352-1358.
17. D'Amico TA, Massey M, Herndon JE III, et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-743.
18. Williams DE, Pariolero PC, Davis CS, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981;123:446-449.
19. Kirby TJ, Mack MJ, Landreneau RJ, et al. Lobectomy-video-assisted thoracic surgery versus muscle-sparing thoracotomy: a randomized trial. J Thorac Cardiovasc Surg 1995;109:997-1002.
20. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac cardiovasc Surg 1995;109:120-129.
21. Thomas PA, Piantadosi S. The Lung Cancer Study Group. Postoperative T1 N0 non-small cell lung cancer. J Thorac Cardiovasc Surg 1987;94:349-354.
22. Ginsberg RJ, Rubinstein LV. Lung Cancer Study Group. Randomized trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer. Ann Thorac Surg 1995;60:615-623.
26. Al-Kattan K, Sepsas E, Fountain SW, et al. Disease recurrence after resection for stage I lung cancer. Eur J Cardiovasc Surg 1997;12:380-384.
27. Naunheim KS, Virgo KS, Coplin MA, et al. Clinical surveillance testing after lung cancer operations. Ann Thorac Surg 1995;60:1612-1616.